Radiolabeled	O
B9958	B:C0002776
Derivatives	I:C0002776
for	O
Imaging	B:C0011923
Bradykinin	B:C0384601
B1	I:C0384601
Receptor	I:C0384601
Expression	B:C1171362
with	O
Positron	B:C0032743
Emission	I:C0032743
Tomography	I:C0032743
:	O
Effect	O
of	O
the	O
Radiolabel	O
-	O
Chelator	B:C0007974
Complex	B:C1704241
on	O
Biodistribution	O
and	O
Tumor	B:C0027651
Uptake	B:C3888108
.	O

Bradykinin	B:C0384601
B1	I:C0384601
receptor	I:C0384601
(	O
B1	B:C0384601
receptor	I:C0384601
)	O
,	O
which	O
is	O
upregulated	B:C0041904
in	O
a	O
variety	O
of	O
malignancies	B:C0006826
,	O
is	O
an	O
attractive	O
cancer	O
imaging	O
biomarker	B:C0005516
.	O

In	O
this	O
study	B:C2603343
we	O
optimized	O
the	O
selection	O
of	O
radiolabel	O
-	O
chelator	B:C0007974
complex	B:C1704241
to	O
improve	O
tumor	B:C0027651
uptake	B:C3888108
and	O
tumor	B:C0027651
-	O
to	O
-	O
background	O
contrast	O
of	O
radiolabeled	O
analogues	O
of	O
B9958	B:C1721886
(	O
Lys	O
-	O
Lys	O
-	O
Arg	O
-	O
Pro	O
-	O
Hyp	O
-	O
Gly	O
-	O
Cpg	O
-	O
Ser	O
-	O
d	O
-	O
Tic	O
-	O
Cpg	O
)	O
,	O
a	O
potent	O
B1R	B:C3850093
antagonist	I:C3850093
.	O

Peptide	B:C0030956
sequences	I:C0030956
were	O
assembled	O
on	O
solid	O
phase	O
.	O

Cold	O
standards	O
were	O
prepared	O
by	O
incubating	O
DOTA	B:C0088359
-/	O
NODA	B:C0029224
-	O
conjugated	B:C0522529
peptides	B:C0030956
with	O
GaCl3	B:C0021521
,	O
and	O
by	O
incubating	O
AlOH	B:C0002371
-	O
NODA	B:C0029224
-	O
conjugated	O
peptide	B:C0030956
with	O
NaF	B:C0037508
.	O

Binding	B:C1167622
affinities	O
were	O
measured	O
via	O
in	B:C0201712
vitro	I:C0201712
competition	I:C0201712
binding	I:C0201712
assays	I:C0201712
.	O

(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
and	O
(	B:C0302995
18	I:C0302995
)	I:C0302995
F	I:C0302995
labeling	B:C0022261
experiments	I:C0022261
were	O
performed	O
in	O
acidic	B:C0006353
buffer	I:C0006353
and	O
purified	O
by	O
HPLC	B:C0008562
.	O

Imaging	B:C0011923
/	O
biodistribution	O
studies	B:C2603343
were	O
performed	O
in	O
mice	B:C0025929
bearing	O
both	O
B1R	B:C0384601
-	I:C0384601
positive	I:C0384601
(	O
B1R	B:C0384601
-	I:C0384601
positive	I:C0384601
)	O
HEK293T	B:C0007634
::	O
hB1R	B:C0007634
and	O
B1R	B:C1513916
-	I:C1513916
negative	I:C1513916
(	O
B1R	B:C1513916
-	I:C1513916
negative	I:C1513916
)	O
HEK293T	B:C0007634
tumors	B:C0027651
.	O

Z02176	B:C0030956
(	O
Ga-	B:C0030956
DOTA	I:C0030956
-	I:C0030956
Pip	I:C0030956
-	I:C0030956
B9958	I:C0030956
;	O
Pip	B:C0031960
:	O
4	B:C0031960
-	I:C0031960
amino	I:C0031960
-(	I:C0031960
1-carboxymethyl	I:C0031960
)	I:C0031960
piperidine	I:C0031960
)	I:C0031960
,	O
Z02137	B:C0030956
(	O
Ga-	B:C0030956
NODA	I:C0030956
-	I:C0030956
Mpaa-Pip	I:C0030956
-	I:C0030956
B9958	I:C0030956
;	O
Mpaa	B:C0070620
:	O
4	B:C0070620
-	I:C0070620
methylphenylacetic	I:C0070620
acid	I:C0070620
)	O
,	O
and	O
Z04139	B:C0030956
(	O
AlF	B:C0030956
-	I:C0030956
NODA	I:C0030956
-	I:C0030956
Mpaa	I:C0030956
-	I:C0030956
Pip	I:C0030956
-	I:C0030956
B9958	I:C0030956
)	O
bound	O
h	O
B1	B:C0384601
receptor	I:C0384601
with	O
high	O
affinity	O
(	O
Ki	O
=	O
1.4	O
-2.5	O
nM	O
)	O
.	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-/	O
(	B:C0302995
18	I:C0302995
)	I:C0302995
F	I:C0302995
-	O
labeled	O
peptides	B:C0030956
were	O
obtained	O
on	O
average	O
in	O
≥	O
32	O
%	O
decay	O
-	O
corrected	O
radiochemical	B:C0599914
yield	O
with	O
>	O
99	O
%	O
radiochemical	B:C0599914
purity	O
and	O
100	O
-	O
261	O
GBq	O
/	O
μmol	O
specific	O
activity	O
.	O

Biodistribution	O
/	O
imaging	B:C0011923
studies	B:C2603343
at	O
1	O
h	O
postinjection	O
showed	O
that	O
all	O
tracers	B:C1522485
cleared	O
rapidly	O
from	O
background	O
tissues	B:C0040300
(	O
except	O
kidneys	B:C0022646
)	O
and	O
were	O
excreted	B:C0221102
predominantly	O
via	O
the	O
renal	B:C0035070
pathway	I:C0035070
.	O

Only	O
kidneys	B:C0022646
,	O
bladders	B:C0005682
,	O
and	O
B1R	B:C0384601
-	I:C0384601
positive	I:C0384601
tumors	B:C0027651
were	O
clearly	O
visualized	O
in	O
PET	B:C0032743
images	B:C1704922
.	O

Uptake	B:C3888108
in	O
B1R	B:C0384601
-	I:C0384601
positive	I:C0384601
tumor	B:C0027651
was	O
higher	O
by	O
using	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-	O
Z02176	B:C0030956
(	O
28.9	O
±	O
6.21	O
%	O
ID/g	O
)	O
and	O
(	B:C0303226
18	I:C0303226
)	I:C0303226
F	I:C0303226
-	O
Z04139	B:C0030956
(	O
22.6	O
±	O
3.41	O
%	O
ID/g	O
)	O
than	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-	O
Z02137	B:C0030956
(	O
14.0	O
±	O
4.86	O
%	O
ID/g	O
)	O
.	O

The	O
B1R+	O
tumor	O
-	O
to	O
-	O
blood	O
and	O
B1R+	O
tumor	O
-	O
to	O
-	O
muscle	O
contrast	O
ratios	O
were	O
also	O
higher	O
for	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-	O
Z02176	B:C0030956
(	O
56.1	O
±	O
17.3	O
and	O
167	O
±	O
57.6	O
)	O
and	O
(	B:C0303226
18	I:C0303226
)	I:C0303226
F	I:C0303226
-	O
Z04139	B:C0030956
(	O
58.0	O
±	O
20.9	O
and	O
173	O
±	O
42.9	O
)	O
than	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-	O
Z02137	B:C0030956
(	O
34.3	O
±	O
15.2	O
and	O
103	O
±	O
30.2	O
)	O
.	O

With	O
improved	O
target	O
-	O
to	O
-	O
background	O
contrast	O
(	B:C0303226
68	I:C0303226
)	I:C0303226
Ga	I:C0303226
-	O
Z02176	B:C0030956
and	O
(	B:C0303226
18	I:C0303226
)	I:C0303226
F	I:C0303226
-	O
Z04139	B:C0030956
are	O
promising	O
for	O
imaging	B:C0011923
B1	B:C0384601
receptor	I:C0384601
expression	B:C1171362
in	O
cancers	B:C0006826
with	O
PET	B:C0032743
.	O

